Aces. TU from me. Reality is this is my first biotech, but as stated b4 can c much greater income vs input/cost than I have come across. In resource, if it hit paydirt and had commercialization within 2 yrs you would expect a p/e of around 2-6 (dependent on resource). ANP already have sufficient stock/drugs to take them through to development. In next announcement, ANP need to be a little less conservative. If someone said to me they needed 5 thou to make 500 thou / yr and had a sound business plan to reach that target I would be hard pressed to pass it down. Send the message to the masses we need 5mil to make 500 mill/ yr and watch them flock. As you stated, anyone with half a mind would put there money where there mouth is. I'll be honest and say I can't give a true indication as to what the value of this company is/will be when phase 1 complete BUT if I came across a company that had potential annual 'profit' of say 150mill with only risk at that stage (after phase 1 complete), I would be happy to invest at market cap of that value (I.e 2yrs out) MOT and maybe others think this timeline a little tight but somavert did 12 wk then 12-18 mth trial after phase 1 to get final approval so why are we any different. Now I profess to have been tought the hard way when investing as I am sure most have in past 2 yrs. This is not as safe as money in the bank but I don't know of a better stock for risk/reward at present
ANP Price at posting:
9.0¢ Sentiment: Buy Disclosure: Held
